<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587365</url>
  </required_header>
  <id_info>
    <org_study_id>CV206-001</org_study_id>
    <nct_id>NCT01587365</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-962476 in Healthy Subjects and in Patients With Hypercholesterolemia on Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To obtain safety and tolerability information in healthy subjects is administered as a single
      dose
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Study Classification: Pharmacokinetics and Pharmacodynamics

        -  Intervention Model: Single Ascending Dose (SAD) study

        -  Allocation: Randomized Non-Stratified
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-962476 as measured by the number of subjects with serious adverse events, deaths or discontinuations due to adverse events (AEs), AEs of injection site reactions, or potentially clinically significant changes in vital signs</measure>
    <time_frame>Up to Day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects of single subcutaneous (SC) and intravenous (IV) doses of BMS-962476</measure>
    <time_frame>Up to Day 43</time_frame>
    <description>Pharmacodynamic effects will be measured by fasting lipid panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of single dose pharmacokinetics (PK) and dose proportionality of BMS-962476 following SC and IV administration</measure>
    <time_frame>17 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of single dose pharmacokinetics (PK) and dose proportionality of BMS-962476 following SC and IV administration</measure>
    <time_frame>17 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the time of last quantifiable plasma concentration [AUC(0-T)] of single dose pharmacokinetics (PK) and dose proportionality of BMS-962476 following SC and IV administration</measure>
    <time_frame>17 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of single dose pharmacokinetics (PK) and dose proportionality of BMS-962476 following SC and IV administration</measure>
    <time_frame>17 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma elimination half-life (T-HALF) of single dose pharmacokinetics (PK) and dose proportionality of BMS-962476 following SC and IV administration</measure>
    <time_frame>17 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CL/F) of BMS-962476 SC Dosing</measure>
    <time_frame>15 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CL) of BMS-962476 IV Dosing</measure>
    <time_frame>17 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss/F) of BMS-962476 SC Dosing</measure>
    <time_frame>15 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) of BMS-962476 IV Dosing</measure>
    <time_frame>15 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute bioavailability (F) of total and free BMS-962476</measure>
    <time_frame>15 time points up to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of anti-BMS-962476 antibodies (immunogenicity) following single SC and IV doses of BMS-962476</measure>
    <time_frame>Up to Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Panel 1: BMS-962476 SC (0.01 mg/Kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-962476 0.01 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2: BMS-962476 SC (0.03 mg/Kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-962476 0.03 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 3: BMS-962476 SC (0.1 mg/Kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 4: BMS-962476 SC (0.3 mg/Kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 5: BMS-962476 IV (0.3 mg/Kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 6: BMS-962476 IV (1.0 mg/Kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-962476 1.0 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-962476</intervention_name>
    <arm_group_label>Panel 1: BMS-962476 SC (0.01 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 2: BMS-962476 SC (0.03 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 3: BMS-962476 SC (0.1 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 4: BMS-962476 SC (0.3 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 5: BMS-962476 IV (0.3 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 6: BMS-962476 IV (1.0 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo matching with BMS-962476</intervention_name>
    <arm_group_label>Panel 1: BMS-962476 SC (0.01 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 2: BMS-962476 SC (0.03 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 3: BMS-962476 SC (0.1 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 4: BMS-962476 SC (0.3 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 5: BMS-962476 IV (0.3 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 6: BMS-962476 IV (1.0 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or Placebo</arm_group_label>
    <arm_group_label>Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy population

               -  Untreated low density lipoprotein cholesterol (LDL-c) ≥ 130 and ≤ 190 mg/dL and
                  triglycerides ≤ 200 mg/dL

               -  Body Mass Index (BMI) of 18 to 35 kg/m2 inclusive

               -  Men and women, ages 18 to 65 years, inclusive

          -  Statin population

               -  Patients with hypercholesterolemia on stable statin therapy for 6 weeks prior to
                  enrollment

               -  At enrollment, LDL-c ≥ 100mg/dL and triglycerides ≤ 200 mg/dL

               -  Patients with controlled hypertension on a stable dose of no more than two
                  antihypertensive drugs

               -  BMI of 18 to 37 kg/m2 inclusive

               -  Men and women, ages 18 to 75 years inclusive

        Exclusion Criteria:

          -  Healthy Population

               -  Subjects with fasting LDL-c &lt; 130 or &gt; 190 mg/dL, or fasting triglycerides &gt; 200
                  mg/dL

               -  Subjects at increased 10-year cardiovascular risk of ≥ 20% based on Framingham
                  risk score

               -  Subjects with any significant acute or chronic medical illness at the time of
                  screening, including history of cancer, known history of sickle cell disease or
                  trait, and known history of thalassemia

          -  Statin population

               -  Patients with fasting LDL-c &lt; 100mg/dL, or fasting triglycerides &gt; 200 mg/dL on
                  statin therapy

               -  Patients on prescription or over the counter lipid-lowering therapy other than
                  statin therapy

               -  Patients with established atherosclerotic vascular disease

               -  Patients with diabetes who are requiring oral or injectable anti-diabetic drug
                  therapy

               -  Patients with uncontrolled hypertension or controlled hypertension requiring more
                  than two antihypertensive drugs

               -  Patients with any significant acute or chronic medical illness that is severe,
                  progressive or uncontrolled at the time of screening

          -  Use of any lipid lowering medication including over the counter products (eg, niacin &gt;
             500 mg; omega-3 fatty acids &gt; 1000 mg; red rice yeast; phytosterols or stanol esters)
             for lipid lowering within 30 days prior to screening visit (42 days for fibrates) with
             the exception of stable statin therapy in the target disease population

          -  Prior treatment with any monoclonal antibody or investigational protein biologic
             within the preceding one year before study drug administration

          -  Concurrent or use within 3 months of study drug administration of marketed or
             investigational systemic or inhaled corticosteroids or other immunosuppressant drugs,
             and within 6 weeks for topical corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Metabolic And Atherosclerosis Research Center/ Medpace Clinical Pharmacology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>September 2, 2013</last_update_submitted>
  <last_update_submitted_qc>September 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

